<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002217</url>
  </required_header>
  <id_info>
    <org_study_id>280D</org_study_id>
    <secondary_id>UNAP 12</secondary_id>
    <secondary_id>NZTA 4005</secondary_id>
    <nct_id>NCT00002217</nct_id>
  </id_info>
  <brief_title>A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs</brief_title>
  <official_title>Combivir, 1592U89, 141W94 Triple Antiretroviral, Experienced Patient Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94
      in patients who previously have used anti-HIV drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT
      tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine/Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amprenavir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  CD4 count greater than 50 cells/mm3.

          -  HIV RNA less than 50,000 copies/ml.

          -  No active AIDS (excluding CD4 count less than 200 cells/mm3).

          -  Ability to comply with dosing schedule and protocol evaluations.

        Prior Medication:

        Allowed:

        AZT or non-nucleoside reverse transcriptase inhibitors (NNRTIs).

        Exclusion Criteria

        Co-existing Condition:

        Patients with any of the following symptoms or conditions are excluded:

          -  Active AIDS (not excluding CD4 count less than 200).

          -  Malabsorption syndrome affecting drug absorption.

          -  Serious medical condition that would compromise safety of the patient.

        Concurrent Medication:

        Excluded:

          -  AZT or NNRTIs.

          -  More than 1 week treatment with any protease inhibitor.

          -  Enrollment in any other investigational drug protocol.

        Patients with the following prior conditions are excluded:

        History of clinically relevant pancreatitis or hepatitis within the past 6 months.

        Required:

        Antiretroviral therapy with either single or double reverse transcriptase inhibitors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anderson Clinical Research</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Henry K, Shaeffer M, Ross L, Johnson M, Fisher R, Liao Q, Graham N. Response to Combivir and abacavir given bid to nucleoside experienced patients is not affected by the presence of the M184V mutation. 6th Conf Retro and Opportun Infect. 1999 Jan 31 - Feb 4 (abstract no 132)</citation>
  </reference>
  <reference>
    <citation>Henry K, Wallace RJ, Bellman PC, Norris D, Fisher RL, Ross LL, Liao Q, Shaefer MS; TARGET Study Team. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. J Infect Dis. 2001 Feb 15;183(4):571-8. Epub 2001 Jan 11.</citation>
    <PMID>11170982</PMID>
  </reference>
  <verification_date>May 1999</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Patient Compliance</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>abacavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
    <mesh_term>Amprenavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

